<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> (Hereditary non-<z:e sem="disease" ids="C0334108" disease_type="Neoplastic Process" abbrv="">polyposis</z:e> <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>/HNPCC) is a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> susceptibility syndrome which is caused by germline mutations in DNA mismatch repair (MMR) genes, in particular MLH1 and MSH2 </plain></SENT>
<SENT sid="1" pm="."><plain>A pathogenic germline mutation in the respective MMR gene is suggested by the finding of a loss of a mismatch repair protein in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue on immunohistochemical staining combined with an early <z:hpo ids='HP_0011007'>age of onset</z:hpo> and/or the familial occurrence of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Pathogenic germline mutations are identifiable in around 60% of patients suspected of <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e>, depending on the familial occurrence </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of the present study was to identify novel susceptibility genes for <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>64 Healthy controls and 64 Lynch syndrome patients with no pathogenic MSH2 mutation but a loss of MSH2 expression in their <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue were screened for rare and disease causing germline mutations in the functional candidate genes ESR1, ESR2, MAX, PCNA, and KAT2A </plain></SENT>
<SENT sid="5" pm="."><plain>Thirty variants were identified, and these were then genotyped in an independent sample of 36 mutation negative <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> patients and 234 controls </plain></SENT>
<SENT sid="6" pm="."><plain>Since a trend towards association was observed for KAT2A, an additional set of 21 tagging SNPs was analyzed at this locus in a final case-control sample of 142 mutation negative <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> patients and 298 controls </plain></SENT>
<SENT sid="7" pm="."><plain>The mutation analysis failed to reveal any <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare disease</z:e>-causing mutations </plain></SENT>
<SENT sid="8" pm="."><plain>No association was found at the single-marker or haplotypic level for any common disease-modifying variant </plain></SENT>
<SENT sid="9" pm="."><plain>The present results suggest that neither rare nor common genetic variants in ESR1, ESR2, MAX, PCNA, or KAT2A contribute to the development of <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> </plain></SENT>
</text></document>